Korean Pharma Asks For Govt Support as MERS Hits Sales
This article was originally published in PharmAsia News
South Korean pharma firms have decided to ask the government to support the industry, which is suffering from sales decline due to the recent outbreak of the Middle East Respiratory Syndrome (MERS) coronavirus. They will ask the government to postpone a planned drug price cut by one year in an effort to overcome the MERS impact and proceed with drug development and globalization programs.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.